• Revenue: $169 million for Q1 2025, a 10% increase year-over-year.
• Organic Revenue Growth: 11% overall, 14% organic non-COVID growth.
• Adjusted Gross Margin: 53.7%, up nearly 450 basis points from last year.
• Adjusted Income from Operations: $23 million, up 72% year-over-year.
• Adjusted Operating Margin: 13.8%, up 490 basis points from Q1 2024.
• Adjusted EBITDA Margin: 19.3% for Q1 2025.
• Adjusted Net Income: $22 million, a 29% increase from Q1 2024.
• Adjusted Diluted EPS: $0.39, up 29% from $0.30 in Q1 2024.
• Cash Position: $697 million at the end of Q1 2025.
• Biopharma Revenue Growth: Over 20% year-on-year, excluding COVID.
• Consumable Revenue Growth: Greater than 20% year-on-year, excluding Proteins.
• Process Analytics Growth: 20% growth, including $1 million from the 908 acquisition.

• Warning! GuruFocus has detected 3 Warning Signs with RGEN.

Release Date: April 29, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Repligen Corp (NASDAQ:RGEN) reported a strong start to 2025 with 11% organic revenue growth in Q1, and 14% organic non-COVID growth.
• The company experienced high growth in its Proteins franchise, outperforming expectations, and Chromatography and Analytics both grew double digits.
• Orders were up high teens year-on-year with all franchises growing double digits, indicating strong demand across the portfolio.
• Repligen Corp (NASDAQ:RGEN) made strategic progress with the acquisition of 908 Devices' bioprocessing portfolio, enhancing its position in new modalities and process analytics technology.
• The company maintained a strong cash position of $697 million at the end of Q1 2025, providing financial flexibility for future investments and acquisitions.

Negative Points

• Repligen Corp (NASDAQ:RGEN) faced challenges in the capital equipment segment, with revenues declining year-on-year due to timing issues.
• China's market performance was weak, representing only 2% of Q1 revenues and orders, highlighting regional challenges.
• The small biotech segment showed weakness, with sales to emerging markets declining by high single digits.
• The company is exposed to potential tariff impacts, particularly in Europe, which could affect revenue and margins if retaliatory duties are imposed.
• Biotech funding decreased significantly in Q1 2025, which could impact the future health of the ecosystem and Repligen Corp (NASDAQ:RGEN)'s growth prospects.

Q & A Highlights

Q: Did the tariffs impact any element of pull forward in your order book this quarter, especially with some of those large CDMO customers? A: Olivier Loeillot, President and CEO, stated that they have not seen any customers trying to accelerate orders in the quarter, including CDMOs. The strong order intake growth from CDMOs was across the board, not just from large ones, and included a strong performance on the OPUS side with orders up more than 50%. ATF adoption is high, with 9 of the top 10 CDMOs already using ATF.

Q: Can you walk us through the various buckets of offsets for the tariff impact on revenue? A: Jason Garland, CFO, explained that they expect less than a 1% sales increase from tariffs, primarily through surcharges passed on to customers. Price increases may offset raw material inflation. The impact on gross margin is expected to be less than 50 basis points, with minimal EPS impact. They are leveraging their manufacturing footprint to mitigate tariff impacts, with 90% of U.S. sales manufactured or exempt from duties.

Q: How do you feel about the trajectory of cell and gene therapy given recent industry news and FDA changes? A: Olivier Loeillot expressed optimism about the mid to long-term prospects for new modalities, despite some short-term challenges. He noted that their largest new modality customer represented less than 3% of total revenue in 2024, and they have not heard of any customers slowing down or canceling trials due to FDA changes.

Q: Could you elaborate on the mix of clinical versus commercial growth and its sustainability? A: Olivier Loeillot mentioned that the mix remains at 65% clinical and 35% commercial, but they have onboarded over $30 million of business into commercial drugs. He anticipates a shift towards a 50/50 mix over the next several years, indicating sustainable growth as more products move from clinical to commercial stages.

Q: What are your thoughts on the recent announcements from large biopharma about onshoring and increasing CapEx plans? A: Olivier Loeillot views these announcements positively, as they suggest additional business for the bioprocessing industry. Repligen has strong relationships with these companies and sees this as a positive tailwind for the next several years, with ongoing discussions already taking place.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.